IP Verse

Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide - EP3954690

The patent EP3954690 was granted to Acerta Pharma on Apr 5, 2023. The application was originally filed on Jul 1, 2016 under application number EP21182842A. The patent is currently recorded with a legal status of "Revoked".

EP3954690

ACERTA PHARMA
Application Number
EP21182842A
Filing Date
Jul 1, 2016
Status
Revoked
May 16, 2025
Grant Date
Apr 5, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBDec 29, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2014155385
DESCRIPTIONWO2013010868
OPPOSITIONWO2013010868
OPPOSITIONWO2015083008
OPPOSITIONWO2015110923
OPPOSITIONWO2017002095
SEARCHWO2013010868

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CARR, Chem. Eng., (19650000), vol. 72, pages 163 - 168-
DESCRIPTION- D'CRUZ et al., OncoTargets and Therapy, (20130000), vol. 6, pages 161 - 176-
DESCRIPTION- HAUSNER, Int. J. PowderMetall., (19670000), vol. 3, pages 7 - 13-
DESCRIPTION- HENDRIKS et al., Nat. Rev. Cancer, (20140000), vol. 14, pages 219 - 231-
DESCRIPTION- JAINO'BRIEN, Oncology, (20120000), vol. 26, pages 1146 - 52-
DESCRIPTION- J. A. WOYACH et al., Blood, (20140000), vol. 123, pages 1810 - 17-
DESCRIPTION- J. L. BINET et al., Cancer, (19770000), vol. 40, pages 855 - 64-
DESCRIPTION- K. R. RAIT. HAN, Hematol. Oncol. Clin. North Am., (19900000), vol. 4, pages 447 - 56-
DESCRIPTION- LARSEN et al., Carbohydr. Res., (20030000), vol. 338, pages 2325 - 2336-
DESCRIPTION- L. Z. RASSENTI et al., N. Engl. J. Med., (20040000), vol. 351, pages 893 - 901-
DESCRIPTION- R. CLAUS et al., J. Clin. Oncol., (20120000), vol. 30, pages 2483 - 91-
DESCRIPTION- SMELICK et al., Mol. Pharmaceutics, (20130000), vol. 10, pages 4055 - 4062-
DESCRIPTION- T. J. HAMBLIN et al., Blood, (19990000), vol. 94, pages 1848 - 54-
OPPOSITION- Bym Stephan, Pfeiffer Ralph, Guny Michael, Hoiberg Charles, Ponchikian Guirag, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950101), vol. 12, no. 7, pages 945 - 954, XP093151405-
OPPOSITION- Chen Dabing, "HYGROSCOPICITY OF PHARMACEUTICAL CRYSTALS A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY", DISSERTATION, THE UNIVERSITY OF MINNESOTA, THE UNIVERSITY OF MINNESOTA, (20090101), DISSERTATION, (20240415), XP093151407-
OPPOSITION- Ema, "Calquence® 100 mg hard capsules", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20201105), ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://ec.europa.eu/health/documents/community-register/2020/20201105149483/anx_149483_en.pdf, XP093190247-
OPPOSITION- Fda, Cder, U.S. Department Of Health And Human Services, "ANDAs: Pharmaceutical Solid Polymorphism Chemistry, Manufacturing, and Controls Information", Guidance for Industry, (20070701), Guidance for Industry, (20240415), XP093151412-
OPPOSITION- Guillory J. Keith, "5. Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", Polymorphism in Pharmaceutical Solids, (19990101), pages 183 - 226, XP093151406-
OPPOSITION- Kirschning Andreas, "Report on crystallization studies of Acalabrutinib according to EP 3 317 281 and comparison of PXRD spectra with those published in Figures 1 and 13 of EP 3 317 281 ", Naturwissenschaftliche Fakultat, Leibniz Universitat Hannove, Leibniz Universitat Hannove, (20220727), pages 1 - 9, Naturwissenschaftliche Fakultat, (20240415), XP093151410-
OPPOSITION- Dejan‐Krešimir Bučar; Robert W. Lancaster; Joel Bernstein, "Disappearing Polymorphs Revisited", Angewandte Chemie International Edition, Verlag Chemie, Hoboken, USA, Hoboken, USA, (20150601), vol. 54, no. 24, doi:10.1002/anie.201410356, ISSN 1433-7851, pages 6972 - 6993, XP072077056
OPPOSITION- Cameron F. Holder, Raymond E. Schaak, "Tutorial on Powder X-ray Diffraction for Characterizing Nanoscale Materials", ACS Nano, American Chemical Society, US, US , (20190723), vol. 13, no. 7, doi:10.1021/acsnano.9b05157, ISSN 1936-0851, pages 7359 - 7365, XP055689306
OPPOSITION- Sun Ye; Zhu Lei; Wu Tian; Cai Ting; Gunn Erica M.; Yu Lian, "Stability of Amorphous Pharmaceutical Solids: Crystal Growth Mechanisms and Effect of Polymer Additives", The AAPS Journal, Springer US, Boston, Boston , (20120321), vol. 14, no. 3, doi:10.1208/s12248-012-9345-6, pages 380 - 388, XP035719263

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents